| Literature DB >> 29805753 |
Ninh B Doan1, Ha S Nguyen1, Hisham S Alhajala2, Basem Jaber3, Mona M Al-Gizawiy4, Eun-Young Erin Ahn5, Wade M Mueller1, Christopher R Chitambar2, Shama P Mirza6, Kathleen M Schmainda4,7.
Abstract
The absence of major progress in the treatment of glioblastoma (GBM) is partly attributable to our poor understanding of both GBM tumor biology and the acquirement of treatment resistance in recurrent GBMs. Recurrent GBMs are characterized by their resistance to radiation. In this study, we used an established stable U87 radioresistant GBM model and total RNA sequencing to shed light on global mRNA expression changes following irradiation. We identified many genes, the expressions of which were altered in our radioresistant GBM model, that have never before been reported to be associated with the development of radioresistant GBM and should be concertedly further investigated to understand their roles in radioresistance. These genes were enriched in various biological processes such as inflammatory response, cell migration, positive regulation of epithelial to mesenchymal transition, angiogenesis, apoptosis, positive regulation of T-cell migration, positive regulation of macrophage chemotaxis, T-cell antigen processing and presentation, and microglial cell activation involved in immune response genes. These findings furnish crucial information for elucidating the molecular mechanisms associated with radioresistance in GBM. Therapeutically, with the global alterations of multiple biological pathways observed in irradiated GBM cells, an effective GBM therapy may require a cocktail carrying multiple agents targeting multiple implicated pathways in order to have a chance at making a substantial impact on improving the overall GBM survival.Entities:
Keywords: acid ceramidase; acid ceramidase inhibitors; carmofur; glioblastoma; radioresistance
Year: 2018 PMID: 29805753 PMCID: PMC5955095 DOI: 10.18632/oncotarget.25247
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Clustered heat map of RNA-seq transcriptomes of U87 and U87-10gy cells
U87 and U87-10gy cells were subjected to RNA sequencing. Experiments were performed in triplicates, and only genes with statically significant changes (~2000 genes) were utilized for the heat map. Green: relatively high expression, Red: relatively low expression. (P < 0.05)
Enriched gene ontology categories of differentially expressed genes following irradiation based on sets of statistically significant upregulated and downregulated genes (P < 0.05)
| Differentially Expressed | Category | |
|---|---|---|
| GO:0007165: Signal transduction | 6.90E–04 | |
| GO:0006351: Transcription, DNA-templated | 7.40E–03 | |
| GO:0008152: Metabolic process | 1.50E–04 | |
| GO:0006915: Apoptotic process | 6.60E–04 | |
| GO:0007155: Cell adhesion | 1.50E–03 | |
| GO:0072332: Intrinsic apoptotic signaling pathway by p53 class mediator | 1.10E–02 | |
| GO:0045746: Negative regulation of Notch signaling pathway | 7.00E–02 | |
| GO:2000406: Positive regulation of T-cell migration | 4.10E–02 | |
| GO:0010759: Positive regulation of macrophage chemotaxis | 5.00E–02 | |
| GO:0002457: T-cell antigen processing and presentation | 9.60E–02 | |
| GO:0002282: Microglial cell activation involved in immune response | 9.60E–02 | |
| GO:0006954: Inflammatory response | 1.60E–04 | |
| GO:0016477: Cell migration | 2.90E–04 | |
| GO:0010718: Positive regulation of epithelial to mesenchymal transition | 4.90E–03 | |
| GO:0001525: Angiogenesis | 2.00E–02 | |
| GO:0008283: Cell proliferation | 2.30E–02 | |
| GO:0016049: Cell growth | 3.00E–02 | |
| GO:0090263: Positive regulation of canonical Wnt signaling pathway | 4.10E–02 | |
| GO:0001666: Response to hypoxia | 2.90E–02 | |
| GO:0000187: Activation of MAPK activity | 7.50E–02 | |
| GO:0004222: Metalloendopeptidase activity | 5.70E–04 | |
| GO:0004522: Ribonuclease A activity | 8.00E–02 | |
| GO:0071356: Cellular response to tumor necrosis factor | 2.30E–04 | |
| GO:0044344: Cellular response to fibroblast growth factor stimulus | 2.50E–02 | |
| GO:0071560: Cellular response to transforming growth factor beta stimulus | 1.90E–02 |
Experiments were performed in triplicates.
Upregulated genes of selected enriched gene ontology categories following irradiation are shown based on sets of statistically significant changes (P < 0.05)
| Gene Ontology Category | Fold change | Gene symbol | Gene description | |
|---|---|---|---|---|
| GO:0010718:Positive regulation of epithelial to mesenchymal transition | 4.90E–03 | 2.32 | BMP and activin membrane bound inhibitor | |
| 2 | GLI pathogenesis related 2 | |||
| 2.23 | axin 2 | |||
| 4.78 | collagen type I alpha 1 chain | |||
| 2.79 | transforming growth factor beta 3 | |||
| GO:0001525: Angiogenesis | 2.00E–02 | 2.46 | C-X-C motif chemokine ligand 8 | |
| 5.1 | EPH receptor B3 | |||
| 2.2 | EPH receptor B4 | |||
| 5.79 | atypical chemokine receptor 3 | |||
| 2 | chondroitin sulfate proteoglycan 4 | |||
| 2.48 | collagen type VIII alpha 1 chain | |||
| 3 | neurexin 3 | |||
| 3.16 | neuron derived neurotrophic factor | |||
| 3.68 | neuropilin 2 | |||
| 2.611 | serpin family E member 1 | |||
| 3.2 | zinc finger CCCH-type containing 12A | |||
| GO:0016049: Cell growth | 3.00E–02 | 14.44 | ROS proto-oncogene 1, receptor tyrosine kinase | |
| 3.07 | endothelin 1 | |||
| 2.43 | interleukin 7 receptor | |||
| 3.16 | neuron derived neurotrophic factor | |||
| 2.79 | transforming growth factor beta 3 | |||
| GO:0008283: Cell proliferation | 2.30E–02 | 2.18 | E2F transcription factor 8 | |
| 4.84 | ERG, ETS transcription factor | |||
| 14.44 | ROS proto-oncogene 1, receptor tyrosine kinase | |||
| 4.47 | anaplastic lymphoma receptor tyrosine kinase | |||
| 2.23 | axin 2 | |||
| 3 | cell division cycle 25A | |||
| 2.02 | chondroitin sulfate proteoglycan 4 | |||
| 4.19 | cytochrome P450 family 1 subfamily A member 1 | |||
| 3.23 | distal-less homeobox 5 | |||
| 2.14 | fascin actin-bundling protein 1 | |||
| 2.76 | fibroblast growth factor 5 | |||
| 2.62 | gastrin releasing peptide receptor | |||
| 5.56 | myosin heavy chain 10 | |||
| 2.47 | pyruvate dehydrogenase kinase 1 | |||
| 2.25 | ubiquitin like with PHD and ring finger domains 1 | |||
| GO:0004222: Metalloendopeptidase activity | 5.70E–04 | 3 | ADAM metallopeptidase domain 12 | |
| 2.79 | ADAM metallopeptidase domain 19 | |||
| 2.59 | ADAM metallopeptidase with thrombospondin type 1 motif 1 | |||
| 2.73 | ADAM metallopeptidase with thrombospondin type 1 motif 14 | |||
| 2.25 | bone morphogenetic protein 1 | |||
| 3.15 | matrix metallopeptidase 12 | |||
| 5.55 | matrix metallopeptidase 3 | |||
| 5.69 | matrix metallopeptidase 7 | |||
| 2.35 | membrane metalloendopeptidase | |||
| 2.4 | teashirt zinc finger homeobox 2 | |||
| GO:0001666: Response to hypoxia | 2.90E–02 | 5.69 | 4-aminobutyrate aminotransferase | |
| 2.73 | BCL2 interacting protein 3 | |||
| 5.6 | carbonic anhydrase 9 | |||
| 4.17 | cytochrome P450 family 1 subfamily A member 1 | |||
| 3.84 | egl-9 family hypoxia inducible factor 3 | |||
| 2.25 | lysyl oxidase like 2 | |||
| 2.72 | mucin 1, cell surface associated | |||
| 10.81 | periostin | |||
| 2.79 | transforming growth factor beta 3 | |||
| 1.80 | Hypoxia-inducible factor 1-alpha | |||
| GO:0016477: Cell migration | 2.90E–04 | 2.32 | BMP and activin membrane bound inhibitor | |
| 2.39 | EPH receptor A3 | |||
| 5.1 | EPH receptor B3 | |||
| 4.84 | ERG, ETS transcription factor | |||
| 2.95 | WW and C2 domain containing 1 | |||
| 2.06 | bradykinin receptor B1 | |||
| 2 | chondroitin sulfate proteoglycan 4 | |||
| 2.41 | collagen type V alpha 1 chain | |||
| 2.14 | fascin actin-bundling protein 1 | |||
| 3.66 | lymphocyte cytosolic protein 1 | |||
| 3.3 | podocalyxin like | |||
| 4.48 | pregnancy specific beta-1-glycoprotein 2 | |||
| 2.83 | syndecan 1 |
Experiments were performed in triplicates.
Downregulated genes of selected enriched gene ontology categories following irradiation are shown based on sets of statistically significant changes (P < 0.05)
| Gene Ontology Category | Fold change | Gene symbol | Gene description | |
|---|---|---|---|---|
| GO:0006915: Apoptotic process | 6.60E–04 | 4.30E–01 | BCL2 binding component 3 | |
| 7.90E–02 | DCC netrin 1 receptor | |||
| 1.90E–01 | PYD and CARD domain containing | |||
| 4.10E–01 | TNF receptor associated factor 5 | |||
| 1.30E–01 | XIAP associated factor 1 | |||
| 4.10E–01 | brain expressed X-linked 2 | |||
| 2.80E–01 | caspase 1 | |||
| 1.60E–01 | cathepsin H | |||
| 2.30E–01 | complement C5a receptor 1 | |||
| 1.50E–01 | engulfment and cell motility 1 | |||
| 4.50E–01 | interleukin 1 beta | |||
| 2.60E–01 | mitogen-activated protein kinase kinase 6 | |||
| 4.70E–01 | nuclear receptor subfamily 4 group A member 1 | |||
| 3.70E–01 | phorbol-12-myristate-13-acetate-induced protein 1 | |||
| 1.10E–03 | secreted frizzled related protein 2 | |||
| 4.80E–01 | tyrosyl-tRNA synthetase | |||
| GO:0072332: Intrinsic apoptotic signaling pathway by p53 class mediator | 1.10E–02 | 3.50E–01 | PERP, TP53 apoptosis effector | |
| 1.90E–01 | PYD and CARD domain containing | |||
| 3.70E–01 | phorbol-12-myristate-13-acetate-induced protein 1 | |||
| 4.40E–01 | zinc finger matrin-type 1 | |||
| 2.60E–01 | zinc finger protein 385D | |||
| GO:2000406: Positive regulation of T-cell migration | 4.10E–02 | 1.90E–01 | PYD and CARD domain containing | |
| 1.40E–01 | TNF receptor superfamily member 14 | |||
| 2.50E–01 | integrin subunit alpha 4 | |||
| GO:0002457: T-cell antigen processing and presentation | 9.60E–02 | 3.80E–01 | intercellular adhesion molecule 1 | |
| 1.30E–01 | raftlin, lipid raft linker 1 | |||
| GO:0002282: Microglial cell activation involved in immune response | 9.60E–02 | 4.70E–01 | interleukin 33 | |
| 4.90E–01 | toll like receptor 3 | |||
| GO:0010759: Positive regulation of macrophage chemotaxis | 5.00E–02 | 8.50E–02 | chemerin chemokine-like receptor 1 | |
| 2.40E–01 | complement C5a receptor 1 | |||
| 8.50E–02 | tumor necrosis factor superfamily member 18 |
Experiments were performed in triplicates.